Accueil › Adénocarcinome de l'œsophage › Texas › Houston
Essais cliniques pour Adénocarcinome de l'œsophage à Houston, TX
12 études pour Adénocarcinome de l'œsophage recherchent des participants dans et autour de Houston (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Recrutement en coursPhase 2/3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Recrutement en coursPhase 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Recrutement en coursPhase 2/3
- University of Texas MD Anderson Cancer Center, Houston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Recrutement en coursPhase 1/2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Recrutement en coursPhase 1
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Recrutement en cours
- The University of Texas MD Anderson Cancer Center, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Recrutement en coursPhase 3
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Recrutement en coursPhase 1
- Normunity Investigational Site, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recrutement en coursPhase 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- MDACC, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Recrutement en coursPhase 2
- M D Anderson Cancer Center, Houston
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Recrutement en coursPhase 2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Essais pour Adénocarcinome de l'œsophage dans d'autres villes
- New York City, NY18 études
- Boston, MA13 études
- Nashville, TN11 études
- Arlington, VA11 études
- Durham, NC10 études
- Baldwin Park, CA9 études
- Jacksonville, FL9 études
- Rochester, MN9 études
- St. Louis, MO9 études
- Queens, NY9 études
- Los Angeles, CA9 études
- Philadelphia, PA8 études
Autres études à Houston
- Cancer du poumon non à petites cellules145 études
- Cancer du sein126 études
- Cancer (tous types)121 études
- Cancer métastatique104 études
- Cancer colorectal102 études
- Cancer de l'ovaire89 études
- Leucémie aiguë myéloïde85 études
- Cancer du poumon78 études
- Cancer de la prostate76 études
- Cancer de l'endomètre68 études
- Cancer du pancréas61 études
- Mélanome59 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.